Gemma Fuster Orellana
Coordinator of the Understanding breast cancer research line
Email: gemma.fuster@uvic.cat
ORCID: 0000-0002-4501-2422
Scientific Profile: URECERCA
She is a senior researcher and her scientific career is focused on molecular and cellular biology, areas that have allowed her to study mainly cancer. She worked on different topics, all of them related to health, including cancer cachexia and breast cancer (BC). She is author of 34 indexed publications, some of which are first, last and corresponding authors in high impact journals, mainly in the field of oncology. She disseminated her results at national and international conferences, and as an invited speaker at university-research centres and medical institutes. She participated in multiple competitive projects as a collaborator and as principal investigator. She enjoyed a pre-doctoral FPI grant, and she received two postdoctoral grants (Juan de la Cierva/Sara Borrell) and an extraordinary PhD award at UB. She supervised 7 TFMs, 3 TFGs, and 2 doctoral theses. Her main scientific interest is focused on the molecular understanding of the most frequent pre-invasive lesions (DCIS) in CM, from the approach of cancer cells and the tumour microenvironment, focusing on the role of neuronal factors. Currently, she is collaborating in one of the TR2Lab research group projects about mechanisms of tissue repair and regeneration.
My last happenings:
Predictive capacity for local disease control of neogenin-1 (NEO1) transcriptional expression in patients with head and neck squamous cell carcinoma
Gemma Fuster has just published a research article in collaboration with Hospital de Sant Pau and Hospital Clínic where the researchers analyse the predictive capacity for local disease control of the transcriptional expression of the neogenin-1 (NEO1) gene in patients with head and neck squamous cell carcinoma (HNSCC). We performed a retrospective neogenin-1 (NEO1) transcriptional study on tumour biopsies from 107 surgically treated HNSCC patients. Neogenin-1 is the receptor for netrin-1 and has been classified as a tumour suppressor gene in some cancers, such as colorectal cancer. In contrast, in this study shows that HNSCC patients with lower [...]
The metamaterial formalism approach to recognize cancer (TETRA)
Original Title (English): "The metamaterial formalism approach to recognize cancer (TETRA)" Objective: establish the material formalism approach as a standardized and accepted method for the detection of cancer without the need for human intervention. Key words: Metamaterial, Cancer, Artificial Intelligence,Machine Learning, Permittivity TR2Lab research team members: Gemma Fuster Early detection and effective treatment of cancer is of critical importance for increasing the chances of patient survival. The rapid development of machine learning (ML) and particularly deep learning has made significant improvements in the accuracy of cancer screening, detection, and monitoring a possibility. However, despite the advantages offered [...]
Gemma Fuster presented the results of La Marató TV3 project about breast cancer resistance in ASEICA 40th anniversary Congress.
The poster communication has been presented in ASEICA 40th anniversary Congress in La Coruña from 14 to 16th november. This work has been the result of a La Marató TV3 project in collaboration with Hospital Germans Trias i Pujol (IGTP) i Institut de Ciències Fotòniques (ICFO). The results of the poster identified a molecular signature as a prediction biomarkers of therapy in breast cancer patients. The original title of the poster communication is NR4A1/3 and HBB as new predictive biomarkers of neoadjuvant responses in breast cancer patients.
